期刊文献+

高分辨率CT扫描对抗肿瘤药物性肺损害的临床应用价值 被引量:3

Clinical application value of high-resolution CT to anticancer drug-induced pulmonary lesions
原文传递
导出
摘要 目的 探讨抗肿瘤药物性肺损害的高分辨率CT(HRCT) 表现及其临床应用价值.方法 回顾性分析诊断明确的12例抗肿瘤药物性肺损害的患者胸部HRCT表现.结果 本组抗肿瘤药物性肺损害HRCT 表现为间质性肺炎和肺纤维化7例,闭塞性细支气管炎伴机化性肺炎2例,嗜酸细胞性肺炎1例,过敏性肺炎2例.结论 抗肿瘤药物性肺损害的影像学表现是非特异性的,HRCT可以清楚的显示肺损害的病理改变,及早发现肺损害并对一些疾病的鉴别诊断有所帮助,对临床制定或修改治疗方案有重要的提示或指导意义. Objective To investigate HRCT findings of anticancer drug-induced pulmonary lesions and its clinical application value. Methods HRCT findings in 12 patients with diagnosis explicit anticancer drug-induced pulmonary lesions were retrospectively analyzed. Results The group of anticancer drug-induced pulmonary lesions HRCT findings of seven cases of interstitial pneumonia and interstitial fibrosis, bronchiolitis obliterans organizing pneumonia two cases, one case of acidophilia granular cell pneumonia, one case of allergic pneumonia. Conclusions HRCT findings of anticancer drug-induced pulmonary lesions are non-specific, and HRCT can clearly show that the pulmonary lesion to the pathological changes, and to detect the pulmonary lesion as soon as possible, develop or modify the clinical treatment has important suggestion or guidance significance.
出处 《中国实用医刊》 2010年第10期16-17,共3页 Chinese Journal of Practical Medicine
关键词 抗肿瘤药物 药物性肺损害 高分辨率体层摄影 Anticancer drug Drug-induced pulmonary lesion High-resolution CT
  • 相关文献

同被引文献25

  • 1久保惠嗣,万献尧.何谓药物性肺损害[J].日本医学介绍,2007,28(3):98-99. 被引量:8
  • 2Sherrod AM, Brufsky A, Puhalla S. A case of late-onset gemcitabine lung toxicity. Clin Med Insights Oncol, 2011, 5:171-176.
  • 3Takatani K, Miyazaki E, Nureki S, et al. High-resolution computed tomography patterns and immunopathogenetic findings in drug-induced pneumonitis. Respir Med, 2008, 102(6) :892-898.
  • 4Kadoyama K, Kuwahara A, Yamamori M, et al. Hypersensitivity reactions to anticancer agents : data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res, 2011, 30:93.
  • 5Bfiasoulis E, Froudarakis M, Milionis H J, et al. Chemotherapy- induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor sup- port. Respiration, 2000, 67(6):680-683.
  • 6Spanos S, Voudiotaki I, Dmssitis I, et al. Cure of gemcitabine-in- duced systemic capillary leak syndrome without corticostemids. J BUON, 2009, 14(4) :728-729.
  • 7Baron D, Mayo A, Kluger Y. Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease. Clin Oncol ( R Coil Radiol), 2006,18 ( 1 ) :90-91.
  • 8Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmo- nary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol, 2009, 27 (9) : 1405-1412.
  • 9Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer,2004, 91 Suppl 2 :$31-37.
  • 10Delaunois LM. Mechanisms in pulmonary toxicology. Clin Chest Med, 2004, 25(1) : 1-14.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部